πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 1,444 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12232492

Disinfection of bacteriophages products using supercritical carbon dioxide

PRECISIONBIOTIX TECHNOLOGIES INC. Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12228572

Enhanced expression of polo-like kinase 3 (PLK3) in human immunodeficiency virus (HIV)-inf

The First Hospital of China Medical University Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226437

Method for enhancing expression of insulin like growth factor 1 receptor in umbilical cord

China Medical University Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227584

Multivalent and multispecific OX40-binding fusion proteins

Inhibrx Biosciences, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12227744

Compositions and methods for inhibiting expression of transthyretin

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221483

Fusion protein and nucleic acid encoding sequence thereof, and uses of the same

China Medical University Hospital Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221610

RNAi agents for inhibiting expression of HIF-2 alpha (EPAS1), compositions thereof, and me

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12215131

IgG Fc-IL2-RΞ±-IL2 fusions and methods of use thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12214218

Perfusion modulated tumor dose sculpting with single dose radiotherapy

FUNDAçÃO D. ANNA DE SOMMER CHAMPALIMAUD E DR. CARLOS MONTEZ CHAMPALIMAUD Β· Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12208227

Precision bio-chemotronic system

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201673

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12201639

Aqueous oral pharmaceutical suspension compositions

ReveraGen BioPharma, Inc. Β· Granted Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12188017

Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin

Arrowhead Pharmaceuticals, Inc. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12186428

Combination taxoid nanoemulsion with immunotherapy in cancer

Northwestern University Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12188020

Methods for reducing Ataxin-2 expression

Ionis Pharmaceuticals, Inc. Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180463

Lactobacillus reuteri

PrecisionBiotics Group Limited Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12181555

3-dimensional representations of post-contrast enhanced brain lesions

The Board of Regents of the University of Texas System Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12171761

Vilazodone inclusion complexes, compositions and preparation thereof

SUNSHINE LAKE PHARMA CO., LTD. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12168036

Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion prot

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12162920

Hinge area and use of same in constructing car skeleton

CHONGQING PRECISION BIOTECH COMPANY LIMITED Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12150777

Treatment of depression

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12151001

Optimized expression cassettes for gene therapy

Tenaya Therapeutics, Inc. Β· Granted Tue Nov 26 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12145974

Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of

SUNSHINE LAKE PHARMA CO., LTD. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12145939

Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators

PRAXIS PRECISION MEDICINES, INC. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted